159 related articles for article (PubMed ID: 26120010)
21. Norgestimate: overview of a monophasic formulation.
Anderson FD; Gillmer MD
Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():126-32. PubMed ID: 8260971
[No Abstract] [Full Text] [Related]
22. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
[TBL] [Abstract][Full Text] [Related]
23. A Drug-Drug Interaction Study to Evaluate the Effect of TAS-303 on CYP3A Activity in the Small Intestine and Liver.
Kumagai Y; Fujita T; Maeda M; Sasaki Y; Nagaoka M; Huang J; Takenaka T; Kawai M
J Clin Pharmacol; 2020 Jun; 60(6):702-710. PubMed ID: 32026490
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol.
Wiesinger H; Berse M; Klein S; Gschwend S; Höchel J; Zollmann FS; Schütt B
Br J Clin Pharmacol; 2015 Dec; 80(6):1399-410. PubMed ID: 26271371
[TBL] [Abstract][Full Text] [Related]
25. Lurasidone drug-drug interaction studies: a comprehensive review.
Chiu YY; Ereshefsky L; Preskorn SH; Poola N; Loebel A
Drug Metabol Drug Interact; 2014; 29(3):191-202. PubMed ID: 24825095
[TBL] [Abstract][Full Text] [Related]
26. Drug-Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 (Bersacapavir).
Vandenbossche J; Yogaratnam J; Hillewaert V; Rasschaert F; Talloen W; Biewenga J; Snoeys J; Kakuda TN; Palmer M; Nangosyah J; Biermer M
Clin Pharmacol Drug Dev; 2022 Dec; 11(12):1419-1429. PubMed ID: 36062869
[TBL] [Abstract][Full Text] [Related]
27. Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization.
Hampton RM; Fisher AC; Pagano S; LaGuardia KD
Fertil Steril; 2009 Aug; 92(2):434-40. PubMed ID: 18930189
[TBL] [Abstract][Full Text] [Related]
28. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women.
Sevinsky H; Eley T; Persson A; Garner D; Yones C; Nettles R; Krantz K; Bertz R; Zhang J
Antivir Ther; 2011; 16(2):149-56. PubMed ID: 21447863
[TBL] [Abstract][Full Text] [Related]
29. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
30. Clinical evidence of the minimal androgenic activity of norgestimate.
Chapdelaine A; Desmarais JL; Derman RJ
Int J Fertil; 1989; 34(5):347-52. PubMed ID: 2571595
[TBL] [Abstract][Full Text] [Related]
31. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
[TBL] [Abstract][Full Text] [Related]
32. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
Einolf HJ; Zhou J; Won C; Wang L; Rebello S
Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
[TBL] [Abstract][Full Text] [Related]
33. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.
Farid NA; Small DS; Payne CD; Jakubowski JA; Brandt JT; Li YG; Ernest CS; Salazar DE; Konkoy CS; Winters KJ
Pharmacotherapy; 2008 Dec; 28(12):1483-94. PubMed ID: 19025429
[TBL] [Abstract][Full Text] [Related]
34. Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review.
Neef D; Berthold HK; Gouni-Berthold I
Expert Rev Clin Pharmacol; 2016; 9(5):655-63. PubMed ID: 26943823
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive.
Devineni D; Skee D; Vaccaro N; Massarella J; Janssens L; LaGuardia KD; Leung AT
J Clin Pharmacol; 2007 Apr; 47(4):497-509. PubMed ID: 17389559
[TBL] [Abstract][Full Text] [Related]
36. Use of endogenous cortisol 6β-hydroxylation clearance for phenotyping in vivo CYP3A activity in women after sequential administration of an oral contraceptive (OC) containing ethinylestradiol and levonorgestrel as weak CYP3A inhibitors.
Shibasaki H; Kuroiwa M; Uchikura S; Tsuboyama S; Yokokawa A; Kume M; Furuta T
Steroids; 2014 Sep; 87():137-44. PubMed ID: 24928723
[TBL] [Abstract][Full Text] [Related]
37. LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design.
Blom DJ; Fayad ZA; Kastelein JJ; Larrey D; Makris L; Schwamlein C; Bloeden L; Underberg J;
J Clin Lipidol; 2016; 10(2):273-82. PubMed ID: 27055957
[TBL] [Abstract][Full Text] [Related]
38. Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women.
Upreti VV; Hsiang CB; Li L; Xu X; LaCreta FP; Boulton DW
Diabetes Obes Metab; 2012 Dec; 14(12):1155-7. PubMed ID: 22776778
[TBL] [Abstract][Full Text] [Related]
39. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
40. Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women.
Roy P; Jakate AS; Patel A; Abramowitz W; Wangsa J; Persiani S; Kapil R
J Clin Pharmacol; 2005 Mar; 45(3):329-36. PubMed ID: 15703367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
